340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs
This article was originally published in The Pink Sheet Daily
A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.
You may also be interested in...
Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.
Berkeley Research Group finds fault with the oft-cited idea that 340B accounts for only 2% of total drug sales. Meanwhile, 340B hospitals issue their own data showing they serve lower-income populations than other hospitals.
House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.